PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

Supported in whole by an educational grant from Apellis Pharmaceuticals, Inc.

PROGRAM OVERVIEW

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare immunologic disorder that leads to the destruction of red blood cells through the complement cascade. Recently, two complement inhibitors (a long-acting C5 inhibitor and antagonist of C3) were approved by the FDA to treat PNH. Several other agents are also in phase 3 development. With these disease-modifying drugs, patients with PNH can now expect to live a relatively normal lifespan, but only if physicians and other members of the healthcare team know how to recognize and diagnose this disease and are familiar with its treatment options. Join expert Dr. Carlos de Castro as he walks through the pathophysiology of PNH, explores the mechanism of action (MOA) of these new agents and their role in treatment, and discusses individualized therapeutic approaches. This video-based activity is complemented with a slide presentation, followed by a puzzle-based game. Challenge yourself though a series of assessments on the complement cascade pathways, key clinical trial information, and safety and side effect profiles of newer therapies to complete the puzzle. The puzzle will reveal the MOA of complement inhibitors recently approved to treat PNH.

FACULTY

Carlos M. de Castro III, MD Professor of Medicine Department of Medicine Duke University Durham, North Carolina

Release date: August 1, 2022 Expiration date: August 1, 2023 Estimated time to complete activity: 60 minutes

TARGET AUDIENCE

This educational program is designed for hematologists, oncologists, and other healthcare providers involved in managing care for patients with PNH, including primary care physicians, physician assistants, and nurse practitioners.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

Explain how the pathophysiology of PNH affects management
Evaluate the MOA of new agents and their place in treatment
Identify patients who are candidates for new PNH therapies

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of August 1, 2022 through August 1, 2023 participants must:

Read the learning objectives and faculty disclosures
Complete the pretest
Study the educational activity
Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

MEDIA

Internet

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity: Carlos M. de Castro, MD Consultant: Alexion Pharmaceuticals, Apellis, Biocryst Data Safety Monitoring Board: Regeneron Researcher: Apellis Speaker: Apellis Steering Committee: Novartis The Integrity Continuing Education, Inc., planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc., does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent) Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS Plug-in: Adobe^® Flash^® Player 10

Adobe^® Flash^® Player 10 plug-in should be downloaded
Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below: Click here for more information on minimum system requirements

DISCLAIMER

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Catalysts and Cascades: Combatting PNH With Complement Inhibitors